XBP1 and glioblastoma: Higher level of XBP1 correlates with lower survival rate and poor prognosis of patients with glioblastoma; conversely, ovarian cancer mouse treated with XBP1-silencing nanoparticles exhibited better prognosis, as compared to control [59,60].